IQVIA (NYSE:IQV) Price Target Cut to $216.00 by Analysts at Truist Financial

IQVIA (NYSE:IQV) had its target price decreased by Truist Financial from $263.00 to $216.00 in a research report sent to investors on Thursday,Benzinga reports. Truist Financial currently has a buy rating on the medical research company’s stock.

Several other analysts have also recently issued reports on the stock. Royal Bank of Canada reissued an “outperform” rating and set a $270.00 price objective on shares of IQVIA in a research note on Monday, February 10th. Morgan Stanley raised their price objective on IQVIA from $245.00 to $250.00 and gave the stock an “overweight” rating in a report on Tuesday, February 11th. Barclays decreased their target price on IQVIA from $255.00 to $235.00 and set an “overweight” rating for the company in a report on Monday, February 3rd. William Blair restated an “outperform” rating on shares of IQVIA in a report on Wednesday, December 11th. Finally, UBS Group dropped their price objective on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Six research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $241.50.

IQVIA Trading Down 9.0 %

Shares of IQVIA stock opened at $142.96 on Thursday. IQVIA has a fifty-two week low of $135.97 and a fifty-two week high of $252.88. The business’s fifty day moving average is $183.41 and its two-hundred day moving average is $200.24. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The firm has a market cap of $25.21 billion, a PE ratio of 19.06, a P/E/G ratio of 1.99 and a beta of 1.46.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Analysts anticipate that IQVIA will post 10.84 earnings per share for the current year.

Institutional Trading of IQVIA

Institutional investors have recently added to or reduced their stakes in the business. American National Bank & Trust acquired a new position in shares of IQVIA in the 1st quarter valued at about $26,000. Synergy Asset Management LLC bought a new position in shares of IQVIA during the fourth quarter valued at approximately $33,000. ST Germain D J Co. Inc. lifted its holdings in shares of IQVIA by 66.1% in the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company’s stock worth $34,000 after purchasing an additional 76 shares during the last quarter. GKV Capital Management Co. Inc. acquired a new position in IQVIA during the 4th quarter valued at approximately $39,000. Finally, Lee Danner & Bass Inc. bought a new position in IQVIA during the 4th quarter worth $44,000. Institutional investors own 89.62% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.